



March 16, 2020

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

(Code Number 4563, Mothers of the TSE)

DNA Vaccine for Hypertension: Enrollment Completed for Phase 1/2a clinical trial in Australia

Tokyo, March 16, 2020 - AnGes Inc. announced that in Phase 1/2a clinical trial in Australia an administration of the DNA vaccine for hypertension was completed to 24 patients as scheduled. Moving forward, an evaluation of the six-month safety and efficacy under double-blinded conditions will be conducted, followed by the evaluation of long-term safety and efficacy, under open-label conditions, for another six months.

< Overview of Phase 1/2a clinical trial of DNA vaccine for hypertension in Australia >

- Study Synopsis: Double-blind, placebo-controlled, clinical study evaluating the safety, tolerability and exploratory efficacy targeting hypertensive patients
- Number of subjects enrolled: 24 subjects
- Observation period: 12 months

The results of the clinical trial are planned to be published around the 4th quarter of 2020.

For details about this study

Australian Clinical Trials

Trial ID: ACTRN12617001192370

<About DNA vaccines for hypertension>

DNA vaccines for hypertension are currently being developed with the aims of creating, inside the body, an antibody (a molecule that binds to target substances because of immune effects) against angiotensin II, an *in vivo* substance having hypertensive actions, and suppressing its actions, thereby treating hypertension. Currently, numerous oral drugs are being used in the treatment of hypertension. Whereas these drugs must be taken everyday without forgetting, DNA vaccines, which are injection agents, are expected to maintain their effects for a long time with a single administration. It will therefore dramatically improve convenience for patients, especially elderly people who find it difficult to take drugs.

The impact this will have on the full-year consolidated results for this fiscal year is currently being examined.

AnGes, Inc.
Public Relations & Investor Relations Group
Contact: <https://www.anges.co.jp/en/contact/>